Neumora Initiates Phase 1b Trial for Alzheimer’s-Related Agitation Treatment
Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced the initiation of a